Neurometrix Inc  

(Public, NASDAQ:NURO)   Watch this stock  
Find more results for NURO
1.91
-0.03 (-1.55%)
May 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.90 - 1.94
52 week 1.84 - 5.10
Open 1.94
Vol / Avg. 6,097.00/14,968.00
Mkt cap 3.96M
P/E     -
Div/yield     -
EPS -5.45
Shares 2.07M
Beta 0.39
Inst. own 14%
Jul 22, 2013
Q2 2013 NeuroMetrix Inc. Earnings Release Add to calendar
May 6, 2013
NeuroMetrix Inc. Annual Stockholders Meeting
Apr 25, 2013
Q1 2013 NeuroMetrix Inc. Earnings Conference Call - Webcast
Apr 22, 2013
Q1 2013 NeuroMetrix Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '12) 2012
Net profit margin -122.96% -132.11%
Operating margin -123.13% -132.30%
EBITD margin - -128.38%
Return on average assets -62.40% -79.75%
Return on average equity -77.49% -100.63%
Employees 55 -
Carbon Disclosure Rating - -

Address

62 4th Avenue
WALTHAM, MA 02451
United States - Map
+1-781-8909989 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

NeuroMetrix, Inc. (NeuroMetrix) is a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes. The Company is focused on the development of products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders, such as those associated with diabetes, carpal tunnel syndrome (CTS), lumbosacral disc disease and spinal stenosis. It markets systems for the performance of nerve conduction studies (NCS) and needle electromyography procedures. The Company markets a variety of consumables and accessories for use with its neurodiagnostic devices. The Company�s initial product for diabetic neuropathy, NC-stat DPNCheck, was launched in September 2011. NC-stat DPNCheck is a fast, accurate, and quantitative nerve conduction test that is used to evaluate systemic neuropathies such as diabetic peripheral neuropathy (DPN).

Officers and directors

Shai N. Gozani M.D., Ph.D. Chairman of the Board, President, Chief Executive Officer, Secretary
Age: 47
Bio & Compensation  - Reuters
Thomas T. Higgins Chief Financial Officer, Senior Vice President, Treasurer
Age: 60
Bio & Compensation  - Reuters
Krishnamurthy Balachandran Senior Vice President, Chief Operating Officer - Neurodiagnostics
Age: 53
Bio & Compensation  - Reuters
Michael Williams Ph.D. Senior Vice President - Engineering, Chief Technology Officer
Age: 55
Bio & Compensation  - Reuters
Guy Daniello Senior Vice President - Information Technology
Age: 67
Bio & Compensation  - Reuters
David E. Goodman M.D. Independent Director
Age: 55
Bio & Compensation  - Reuters
Allen J. Hinkle M.D. Independent Director
Age: 61
Bio & Compensation  - Reuters
Nancy E. Katz Independent Director
Age: 52
Bio & Compensation  - Reuters
Timothy R. Surgenor Independent Director
Age: 52
Bio & Compensation  - Reuters